Key result
SGLT2 inhibitors show potential to improve right ventricular function in pulmonary hypertension.
Why the study?
Do SGLT2 inhibitors improve right ventricular function in patients with pulmonary hypertension?
Do SGLT2 inhibitors improve right ventricular function in patients with pulmonary hypertension?
This review highlights the emerging potential of SGLT2 inhibitors to improve right ventricular function in pulmonary hypertension, emphasizing the need for dedicated clinical trials.
Inhibiting SGLT2 (sodium-glucose cotransporter 2) has recently transformed the medical care of patients with left heart disease. Right ventricular failure is a major predictor for patients suffering from pulmonary hypertension of various causes, including those with postcapillary pulmonary hypertension due to left heart disease. Similar to how SGLT2 inhibition benefits patients with left heart failure, recent studies have suggested utilizing these molecules to enhance right ventricular function in pulmonary hypertension. In this review, we summarize the current knowledge on the use of SGLT2is (SGLT2 inhibitors) in pulmonary hypertension. Further dedicated trials are necessary to establish their role in right ventricular pulmonary vascular disease.
No takes yet. Share an insight, caveat, or question.
Aguado et al. (2025) conducted a review in Pulmonary hypertension. SGLT2 inhibitors was evaluated. SGLT2 inhibitors show potential to enhance right ventricular function in pulmonary hypertension, but further dedicated trials are required to establish their clinical role.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: